Recent Updates
Recently added Catalysts
PYXS Positive Sentiment Score: 70/100

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

Key Takeaway: Pyxis Oncology, Inc. (NASDAQ: PYXS) will have its CEO Lara S. Sullivan participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024. This event will take place at 9:00 AM Eastern Time in New York City and includes opportunities for investor one-on-one meetings. The presentation will be available for live streaming and replay on the company's Investor Relations website, enhancing accessibility.

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • CEO Lara S. Sullivan will represent the company at a notable conference.
  • Opportunity for investor engagement through one-on-one meetings.
  • Presentation will be accessible via live webcast, increasing visibility.

Full Press Release Details

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, June 6, 2024 at 9:00 AM Eastern Time at the Jefferies Global Healthcare Conference in New York City, where members of management will also host investor one-on-one meetings.
A live webcast and replay of the presentation will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.
About Pyxis Oncology, Inc.
Forward Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “to be,” “will,” “would,” or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled “Risk Factors” set forth in Part II, Item 1A. of the Company’s Annual Report on Form 10-K filed with SEC on March 21, 2024, and our other filings, each of which is on file with the Securities and Exchange Commission. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.
Pyxis Oncology Contact

Frequently Asked Questions

When is the Pyxis Oncology fireside chat scheduled?

The fireside chat is on June 6, 2024, at 9:00 AM Eastern Time.

Where will the Pyxis Oncology presentation be available?

It will be on the Events & Presentations page of Pyxis Oncology's website.

Who is the CEO of Pyxis Oncology?

Lara S. Sullivan, M.D., is the President and CEO of Pyxis Oncology.

What is Pyxis Oncology's focus?

Pyxis Oncology focuses on developing therapeutics for difficult-to-treat cancers.

How can I contact Pyxis Oncology for investor inquiries?

You can reach Pyxis Oncology at ir@pyxisoncology.com.

Last updated: May 30, 2024